Consistently, preclinical studies using genetic or antibody-mediated TLR2 blockade (e.g., OPN-301) inhibited tumorigenesis in gastric and pancreatic carcinomas, and head and neck cancers [201]. This evidence concerns the gene TLR2 and head and neck cancer.